Olutasidenib Drug Asset Due Diligence Report 2026

This Olutasidenib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Olutasidenib can convert its Small molecule drug profile and IDH1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Olutasidenib (query alias: olutasidenib)
Modality / target	Small molecule drug; IDH1; IDH1 inhibitors, Epigenetic drug
Highest global status	Approved
Originator	Forma Therapeutics Holdings, Inc.
Active developers	Rigel Pharmaceuticals, Inc., The University of Texas MD Anderson Cancer Center, Kissei Pharmaceutical Co., Ltd.

The MCP disease footprint includes IDH1 Mutation Acute Myeloid Leukemia, Refractory acute myeloid leukemia, Astrocytoma, IDH-Mutant. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07486713	Phase 4	Recruiting	16	Area Under the Plasma Concentration-Time Curve (AUC) of Probe Drugs
NCT07471841	Phase 2	Recruiting	25	Composite complete remission rate
NCT07604064	Phase 2	Recruiting	3	Incidence of adverse events and adverse drug reactions

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Treatment patterns and outcomes with olutasidenib after venetoclax in IDH1-mutated AML using real-world data from a chart review.

Not Applicable; n=51; evaluation: Positive. Reported fields: Adverse Event: Common adverse events = The most common adverse events were fatigue (11.8%), infection, neutropenia, and nausea (each 7.8%).

Real-world treatment patterns and outcomes with olutasidenib after venetoclax in IDH1-mutated AML using EHR data.

Not Applicable; n=24; evaluation: Positive. Reported fields: Adverse Event: disease progression = The most common reason for OLU discontinuation was disease progression

ACUTE MYELOID LEUKEMIA (AML) PATIENT, DISEASE, AND MOLECULAR CHARACTERISTICS ASSOCIATED WITH A LONG-TERM RESPONSE TO OLUTASIDENIB

Phase 2; n=147; evaluation: Positive. Reported fields: AE(≥Grade 3) = Nine (35%) patients experienced grade ≥3 all-cause AEs after 12 mo (only 1 AE in >1 patient [Coronavirus infection]) % ; AE(≥Grade 3) = 35.0 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Olutasidenib addresses IDH1 Mutation Acute Myeloid Leukemia, Refractory acute myeloid leukemia, Astrocytoma, IDH-Mutant. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 6 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2026-05-01	OEP to develop and commercialize Kissei Pharmaceutical's Olutasidenib against acute myeloid leukemia in Taiwan	Approved	Financial terms not disclosed
2026-01-07	Onco360® Has Partnered with Rigel Pharmaceuticals to Add Three Therapies to Its Limited Distribution Portfolio	Approved	Financial terms not disclosed
2024-11-01	Dr. Reddy's Laboratories to develop and commercialize Rigel’s REZLIDHIA in all potential indications in various regions	Approved	US$4.0M upfront; US$36.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Treatment of CNS tumors with olutasidenib and temozolomide”. The milestone feed surfaced a patent-application signal described as “Treatment of acute myeloid leukemia with olutasidenib, venetoclax and a hypomethylating agent”. The milestone feed surfaced a patent-application signal described as “Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO